Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › NVCT

Nuvectis Pharma

NVCT Rare disease Lead: Phase 3 10 Biotech Distilled articles ↓ 25 filings & releases ↓ Cash $141M (Sep 30, 2026) ↓ 10 verdicts ↓ 1 timing quote ↓
HematologyOncologyRenal Small Molecule

Market cap $719M 34.4M shares (10-Q, Oct 30, 2026) × $20.91 close Nov 6, 2026

Most recent annual filing: 2026-02-11

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. NXP200 U.S. IND filing4Q 2026NXP200 U.S. IND filing, 4Q 2026, material
  2. NXP900 Ph1 readout1H 2027NXP900 Ph1 readout, 1H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Discontinued (1)

Capital (as filed)

Cash
$141M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$25.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$141M cash, runway 2H 2029 per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (10)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on Nuvectis Pharma, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-06-02 Watch Nuvectis Pharma (NVCT) — Scientific Deep Dive for NXP900 Differentiated SRC/YES1 conformation-locking mechanism with real PD receipts, but no human efficacy data, a single patent family expiring 2036, and a binary summer readout racing a dilutive raise make this a wait-for-data situation.
  2. 2026-06-23 Speculative buy speculative UPDATE: Nuvectis Pharma (NVCT) - The One-Asset Company Just Bought Two More The Haisco licensing deal converts a one-asset Phase 1a binary into a diversified three-program story with late-stage Factor B and BRAF assets, but the deal is conditional on a raise that hasn't priced, warranting an engaged but cautious speculative position.
  3. 2026-06-30 Speculative buy speculative UPDATE: Nuvectis Pharma (NVCT) - The Deal Priced Below My Yellow Flag The $20 print with a retail-tilted six-co-manager syndicate at a 30% discount-to-last is a yellow-flag outcome, but the Haisco financing condition is retired at 2x the floor and the thesis itself is intact; the institutional sponsorship question now rests on upcoming 13G filings.
  4. 2026-06-30 Speculative buy speculative UPDATE: Nuvectis Pharma (NVCT) - The Financing Print I Was Waiting For The Cantor-led marketed offering resolves the financing-condition overhang on the Haisco deal at a radically better price than modeled, retiring the binary financing risk, though the final discount and allocation quality remain unknowns.
  5. 2026-07-24 Speculative buy speculative UPDATE: Nuvectis Pharma (NVCT) - The Portfolio Anchor Just Cleared a Regulator Ciprocopan's NMPA approval as the world's first once-daily oral Factor B inhibitor validates the mechanism and the head-to-head Soliris data, but the institutional register remains empty and the ex-China regulatory framing is still needed to re-rate the stock.
  6. 2026-08-05 Speculative buy speculative UPDATE: Nuvectis Pharma (NVCT) - The Summer Binary Just Quietly Became a Winter Footnote The thesis has rotated from a one-asset SRC/YES1 binary to a late-stage complement company fully funded into 1H 2029 with a U.S. regulatory clock starting 4Q2026, though NXP900's readout slipped from summer to year-end and narrowed to combinations only.
  7. 2026-08-07 Speculative buy speculative UPDATE: Nuvectis Pharma (NVCT) - The Empty Register Just Got Its First Name Soleus Capital's 5.1% 13G filing partially redeems the retail-syndicate concern from the June 30 print, confirming at least one healthcare-dedicated specialist underwrote the thesis, though one holder is a foothold not a crowded register.
  8. 2026-08-22 Speculative buy speculative UPDATE: Nuvectis Pharma (NVCT) - A $200M Shelf and a Jefferies ATM, Seven Weeks After "Runway Into 1H 2029" The new $200M shelf and $75M Jefferies ATM represent opportunistic financial flexibility at 2.4x the Haisco-announcement price, but a live drip facility caps near-term upside on a stock that has run 25% in two weeks on no new data.
  9. 2026-10-27 Speculative buy speculative UPDATE: Nuvectis Pharma (NVCT) - The Lottery Ticket Shows Its Numbers NXP200's ESMO oral confirmed the 40% glioma response rate with deep tumor shrinkage and clean tolerability, validating the paradox-breaker mechanism, though a ~7-month median DOR in high-grade glioma and no non-V600 data keep it the speculative leg.
  10. 2026-11-05 Speculative buy speculative UPDATE: Nuvectis Pharma (NVCT) - The ATM Found One Big Buyer, and the Canary Slipped Again The balance sheet is the strongest in company history with $140.7M cash and a second large healthcare-fund cheque at $23.36, but NXP900 slipped again to 1H 2027 and the ciprocopan U.S. path now hinges on an ambitious ask of FDA to accept Chinese-only data.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 23, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)